	Total	Intervention	Control	P value
Baseline characteristics				
Age (years)	61±15	60±17	61±14	0.77
Male	31/36 (86%)	15/18 (83%)	16/18 (89%)	>0.99
Hypertension	15/36 (42%)	8/18 (44%)	7/18 (39%)	>0.99
Hypercholesterolemia	14/36 (39%)	8/18 (44%)	6/18 (33%)	0.73
Diabetes	6/36 (17%)	4/18 (22%)	2/18 (11%)	0.65
Previous myocardial infarction	8/36 (22%)	5/18 (28%)	3/18 (17%)	0.69
Previous PCI	5/36 (14%)	2/18 (11%)	3/18 (17%)	>0.99
Previous CABG	3/36 (8%)	2/18 (11%)	1/18 (6%)	>0.99
Ethnicity				
Caucasian	16/36 (44%)	8/18 (44%)	8/18 (44%)	>0.99
Asian	3/36 (8%)	1/18 (6%)	2/18 (11%)	>0.99
Afro-Caribbean	0/36 (0%)	0/18 (0%)	0/18 (0%)	>0.99
Other	4/36 (11%)	2/18 (11%)	2/18 (11%)	>0.99
Unknown	5/36 (36%)	7/18 (39%)	6/18 (33%)	>0.99
IHD	11/36 (31%)	6/18 (33%)	5/18 (28%)	>0.99
Smoking history	7/36 (19%)	4/18 (22%)	3/18 (17%)	>0.99
Event Characteristics				
Preceding symptoms	12/36 (33%)	8/18 (44%)	4/18 (22%)	0.29
Public	29/36 (81%)	14/18 (78%)	15/18 (83%)	>0.99
Bystander CPR	22/36 (61%)	10/18 (56%)	12/18 (67%)	0.73
Presenting rhythm VF	36/36 (100%)	18/18 (100%)	18/18 (100%)	>0.99
Refractory VF	6/36 (17%)	3/18 (17%)	3/18 (17%)	>0.99
LAS Interventions				
Shock required	36/36 (100%)	18/18 (100%)	18/18 (100%)	>0.99
Time to ROSC, mins	18 (8 to 31)	16 (6 to 29)	19 (8 to 36)	0.49
Duration of resuscitation, mins	19 (7 to 31)	17 (7 to 33)	19 (7 to 31)	0.79
Number of shocks	4 (2 to 9)	3 (1 to 8)	4 (2 to 9)	0.73
Amiodarone required	20/36 (56%)	11/18 (61%)	9/18 (50%)	>0.99
Amidoarone dose, mg	0 (0 to 300)	300 (0 to 300)	0 (0 to 300)	0.69
Adrenaline required	21/36 (58%)	11/18 (61%)	10/18 (56%)	>0.99
Adrenaline dose, mg	1 (0-6)	1 (0 to 8)	2 (0 to 6)	0.75
Pre-hospital ROSC	28/36 (78%)	14/18 (78%)	14/18 (78%)	>0.99
Intubated	15/36 (42%)	10/18 (56%)	5/18 (28%)	0.18
GCS on arrival	3 (3 to 10)	3 (3 to 4)	4 (3 to 14)	0.19
Mechanical CPR	17/36 (47%)	9/18 (50%)	8/18 (44%)	>0.99
ECG characteristics				
12 lead	27/36 (75%)	13/18 (72%)	14/18 (78%)	>0.99
ST elevation	4/36 (11%)	3/18 (17%)	1/18 (6%)	0.60

Table 1 Baseline characteristics, cardiac arrest event characteristics, time intervals from cardiac arrest to defined events and London ambulance service (LAS) interventions for the pilot trial. Categorical variables are presented as counts and percentages n/N (%); age is presented as mean±SD; times, Glasgow coma scale (GCS) and drug dosages are displayed as median (interquartile range, IQR). Abbreviations: PCI percutaneous coronary intervention, CABG coronary artery bypass graft surgery, IHD ischaemic heart disease, CPR cardiopulmonary resuscitation, VF ventricular fibrillation, ROSC return of spontaneous circulation, GCS Glasgow coma scale, ECG electrocardiogram.

	Total	Intervention	Control	P value
Angiogram	32/36 (89%)	18/18 (100%)	14/18 (78%)	0.10
Time to Angiography (minutes)		100; 75 to 113	132; 93 to 187	0.08
Coronary Artery Disease (>50% stenosis)	20/32 (63%)	12/18 (67%)	8/14 (57%)	0.72
Number of diseased vessels				
0	10/32 (31%)	6/18 (33%)	4/14 (21%)	>0.99
1	4/32 (13%)	2/18(11%)	2/14 (14%)	>0.99
2	4/32 (13%)	2/18(11%)	2/14 (14%)	0.47
≥3	12/32 (38%)	8/18 (44%)	4/14 (29%)	0.47
Unknown	2/32 (6%)	0/32 (0%)	2/14 (6%)	0.18
Culprit: Revascularisation	15/32 (47%)	8/18 (44%)	7/14 (50%)	0.71
1. PCI	13/15 (87%)	7/8 (88%)	6/7 (86%)	>0.99
LMS	0/13 (0%)	0/7 (0%)	0/6 (0%)	>0.99
LAD	5/13 (38%)	3/7 (43%)	2/6 (33%)	>0.99
Cx	3/13 (23%)	1/7 (14%)	2/6 (33%)	0.56
RCA	5/13 (38%)	3/7 (43%)	2/6 (33%)	>0.99
2. CABG	2/15 (13%)	1/8 (13%)	1/7 (14%)	>0.99

Table 2 Angiographic characteristics of the intervention and control arm. Categorical variables are presented as counts and percentages n/N (%); times are displayed as mean±SD. Abbreviations: PCI percutaneous coronary intervention, LMA left main stem, LAD left anterior descending artery, CX circumflex artery, RCA right coronary artery, CABG coronary artery bypass grafting.

	Total	Intervention	Control	OR (95% CI)*	P value
Primary Endpoint					
30-day all cause mortality	15/33 (45%)	9/18 (50%)	6/15 (40%)	0.6 (0.2 to 2.9)	0.73
Secondary Endpoints					
CPC 1/2 at 30 days	16/32 (50%)	9/18 (50%)	7/14 (50%)	1.0 (0.3 to 3.6)	>0.99
MACCE*	19/33 (58%)	11/18 (61%)	8/15 (53%)	1.4 (0.4 to 4.9)	0.73
Death	15/33 (45%)	9/18 (50%)	6/15 (40%)	0.6 (0.2 to 2.9)	0.73
MI	0/33 (0%)	0/18 (0%)	0/15 (0%)	N/A	>0.99
Further revascularization	3/33 (9%)	1/18(6%)	2/15 (13%)	0.4 (0 to 3.7)	0.58
Stroke	1/33 (3%)	1/18 (6%)	0/15 (0%)	N/A	>0.99
Bleeding	1/33(3%)	1/18 (6%)	0/15 (0%)	N/A	>0.99
Vascular complications	1/33 (3%)	0/18 (0%)	1/15 (7%)	0 (0 to 7.5)	0.5
6-month all cause mortality	15/27 (56%)	9/17 (53%)	6/10 (60%)	0.75 (0.2 to 3.8)	>0.99
Length of Stay*	4.5 (0 to 11)	4.5 (0 to 7.3)	4.5 (0 to 19)	0 (-2 to 8)	0.19
CPR Related Complications	1/33 (3%)	1/18 (6%)	0/15 (0%)	N/A	>0.99
Renal Replacement Therapy	2/33 (3%)	1/18 (6%)	1/15 (7%)	0.8 (0 to 17)	>0.99
Sepsis	11/33 (33%)	6/18 (33%)	5/15 (33%)	1.0 (0.2 to 4.5)	>0.99
Mechanical Circulatory Support	6/33 (18%)	4/18 (22%)	2/15 (13%)	1.6 (0.3 to 9.5)	0.68

Table 3 Primary and secondary outcomes, length of stay and other in-hospital complications described overall and for both arms of the trial. Categorical variables are presented as counts and percentages n/N (%); *days are displayed as median and interquartile range (IQR). Abbreviations: CPC cerebral performance category score, MACCE major adverse cardiovascular and cerebrovascular events, CPR cardiopulmonary resuscitation.